For Immediate Distribution

August 10, New York, NY—WallachBeth Capital LLC (“WB”), the institutional brokerage firm specializing in
order execution for exchange-traded products (ETPs), option strategies and large block equities, announced its
further expansion with the creation of the WallachBeth Healthcare Research Group, an institutional equity research
unit that includes a team of six senior industry veterans who recently joined WallachBeth from Auriga USA, the US
subsidiary of Madrid-based Auriga Global Investors.
The WallachBeth Healthcare Research Group combines the firm’s agency-execution services with a proprietary,
bottoms-up fundamental equity research platform. The new group will focus on providing clients with detailed
company analysis, information flow, conflict-free investment ideas, and access to industry thought leaders across
key healthcare verticals including Life Science Tools, Diagnostics, Clinical Labs, Specialty Pharmaceuticals,
Biotech and Healthcare Services.

WallachBeth Capital CEO Michael Wallach said, “We formed a small boutique less than five years ago with a
mandate to provide conflict-free, integrity-rich best execution services for both institutions and sell-side liquidity
providers. The marketplace has clearly embraced this model; we’ve since grown exponentially and now have a 50+
team of professionals serving a broad and widely-recognized client base in multiple product areas. Our offering a
value-added, proprietary equity research product specific to innovative companies within the Healthcare vertical
enables us to extend our role as a niche provider of in-demand, yet under-served markets, and further complements
our mission to provide true best execution.”

Senior Managing Directors Douglas Bantum and Gene McNeil Jr. will lead the new WallachBeth division. Bantum
and McNeil most recently served as Co-Head(s) of Equity Sales and Trading for Auriga USA and previously
worked together as Senior Vice Presidents for the institutional research boutique Capstone Investments.
Collectively, they have nearly 40 years experience specializing in institutional equity sales/trading and block trade
execution

Additional members of the WallachBeth research team include Senior Equity Research Sales/Trader Anthony
Politi; Director of Research and Life Science Tools and Biotechnology Senior Analyst Peter McDonald; Bloomberg

top-ranked Senior Healthcare Services Analyst Glen Losev; and Biotech & Specialty Pharmaceuticals analyst Difei
Yang, Ph.D. Dr. Yang holds a Doctorate in Chemistry from University of California, an MBA from Georgia State
University, and a B.Sc. in Physics from Peking University in China. Additionally, Dr Yang holds multiple US
patents and has evaluated new business opportunities ranging from pre-clinical to Phase III development

About WallachBeth Capital LLC

WallachBeth Capital LLC operates on a fully-disclosed, agency-only basis while serving the needs of select
institutional fund managers, registered investment advisors (RIAs), premiere hedge funds, Tier 1 sell-side trading
desks, and sophisticated professionals who are focused on the wide-spectrum of Exchange Traded Products (ETPs)
Closed-End Funds (CEFs), exchange-listed and OTC equity options, listed and OTC equities, and non-US equities.
WallachBeth is a member of FINRA, SIPC, NYSE ARCA, CBSX, and ISE. All transactions are cleared through
Bank of America Merrill Lynch’s Broadcort Division®. The firm’s website is located at www.wallachbeth.com.

For Additional Information:

David Beth, President & Chief Operating

Officer
Telephone:

646.237.8590